PDCD1 and atherosclerosis: In this study, we discovered that the treatment with Fc-binding anti-PD-1 mAb (e.g., Nivolumab) could reduce the sizes of AS plaques and potentially resolve human atherosclerosis, based on a retrospective cohort analysis.